Galapagos (GLPG) Projected to Post Earnings on Wednesday

Galapagos (NASDAQ:GLPG) is expected to be releasing its Q4 2025 results before the market opens on Wednesday, February 11th. Analysts expect Galapagos to post earnings of $0.85 per share for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 7:00 AM ET.

Galapagos Stock Performance

GLPG stock opened at $34.60 on Wednesday. Galapagos has a 1-year low of $22.36 and a 1-year high of $37.78. The business has a fifty day moving average price of $32.78 and a 200-day moving average price of $32.61.

Wall Street Analysts Forecast Growth

GLPG has been the topic of a number of recent analyst reports. Leerink Partners raised Galapagos from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 22nd. Wall Street Zen raised shares of Galapagos from a “sell” rating to a “hold” rating in a research note on Tuesday, December 30th. Royal Bank Of Canada boosted their target price on Galapagos from $28.00 to $32.00 and gave the company a “sector perform” rating in a research report on Friday, November 7th. Weiss Ratings reiterated a “sell (d)” rating on shares of Galapagos in a report on Thursday, January 22nd. Finally, Sanford C. Bernstein started coverage on shares of Galapagos in a research note on Wednesday, November 26th. They issued a “hold” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and an average price target of $31.33.

Hedge Funds Weigh In On Galapagos

Hedge funds and other institutional investors have recently bought and sold shares of the business. National Bank of Canada FI purchased a new position in Galapagos during the third quarter valued at approximately $494,000. Bank of America Corp DE lifted its stake in shares of Galapagos by 2.1% in the 3rd quarter. Bank of America Corp DE now owns 30,949 shares of the biotechnology company’s stock valued at $1,072,000 after purchasing an additional 643 shares during the period. Aquatic Capital Management LLC boosted its holdings in Galapagos by 63.6% during the third quarter. Aquatic Capital Management LLC now owns 17,516 shares of the biotechnology company’s stock worth $607,000 after buying an additional 6,807 shares in the last quarter. Ameriprise Financial Inc. boosted its holdings in Galapagos by 2,490.1% during the third quarter. Ameriprise Financial Inc. now owns 1,416,934 shares of the biotechnology company’s stock worth $49,083,000 after buying an additional 1,362,229 shares in the last quarter. Finally, Man Group plc acquired a new stake in Galapagos during the third quarter valued at $1,254,000. Institutional investors and hedge funds own 32.46% of the company’s stock.

About Galapagos

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.